# US 2017/0281589 A1 · Use of sting agonists to treat chronic hepatitis b virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281589 A1
- Document ID: US20170281589A1
- Status: Published application
- Kind: A1
- Application number: 15/483,645
- Filed: 2017-04-10
- Published: 2017-10-05
- Earliest claimed: 2013-10-21
- Assignees: Drexel University
- Applicants: Drexel University
- Inventors: JINHONG CHANG; FANG GUO; TIMOTHY M. BLOCK; JU-TAO GUO
- Web page: https://patentgrep.com/patent/US20170281589A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/706: {for hepatitis}
- G01N 33/5067: {Liver cells}
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/02: Hepadnaviridae, e.g. hepatitis B virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

## Claims

### Claim 1

A method of treating a subject having a hepatitis B viral infection, the method comprising administering an effective amount of a STING agonist to said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said STING agonist stimulates an innate cytokine response in macrophages, dendritic cells, liver non-parenchymal cells, or any combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein said innate cytokine response is mediated through cytokines.

### Claim 4 (depends on 3)

The method of claim 3, wherein said innate cytokine response is mediated through type 1 interferon.

### Claim 5 (depends on 1)

The method of claim 1, wherein said STING agonist comprises a flavonoid.

### Claim 6 (depends on 5)

The method of claim 5, wherein said flavonoid comprises 10-(carboxymethyl) 9(10H)acridone (CMA), 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), methoxyvone, 6,4′-dimethoxyflavone, 4′-methoxyflavone, 3′,6′-dihydroxyflavone, 7,2′-dihydroxyflavone, daidzein, formononetin, retusin 7-methyl ether, xanthone, or any combination thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein said flavonoid comprises DMXAA.

### Claim 8 (depends on 1)

The method of claim 1, wherein said STING agonist suppresses hepatitis B virus replication in infected hepatocytes.

### Claim 9 (depends on 8)

The method of claim 8, wherein said STING agonist reduces hepatitis B virus capsid levels.

### Claim 10

A method of identifying compounds useful in the treatment of hepatitis B virus infection, the method comprising:
treating liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof with a compound of interest;
incubating the treated cells in a conditioned medium;
removing the conditioned medium or a portion thereof from the treated cells; and
incubating hepatitis B virus infected hepatocytes with the conditioned medium.

### Claim 11 (depends on 10)

The method of claim 10, further comprising measuring hepatitis B virus replication.

### Claim 12 (depends on 10)

The method of claim 10, wherein the treating step stimulates an innate cytokine immune response within the liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, and release of cytokines into the conditioned medium.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cytokines include Type I interferons.

### Claim 14 (depends on 10)

The method of claim 10, wherein the conditioned medium suppresses hepatitis B replication in the infected hepatocytes.

### Claim 15

A method of treating a subject having a hepatitis B virus infection, the method comprising:
treating liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, with a compound of interest;
incubating the treated cells in a conditioned medium;
removing the conditioned medium or a portion thereof from the treated cells; and
administering the conditioned medium or a portion thereof to said subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein said compound of interest comprises one or more STING agonists.

### Claim 17 (depends on 16)

The method of claim 16, wherein said STING agonist comprises a flavonoid.

### Claim 18 (depends on 17)

The method of claim 17, wherein said flavonoid comprises 10-(carboxymethyl)-9(10H)acridone (CMA), 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), methoxyvone, 6,4′-dimethoxyflavone, 4′-methoxyflavone, 3′,6′-dihydroxyflavone, 7,2′-dihydroxyflavone, daidzein, formononetin, retusin 7-methyl ether, xanthone, or any combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein said flavonoid comprises DMXAA.

### Claim 20 (depends on 15)

The method of claim 15, wherein the liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, are human cells.

### Claim 21 (depends on 15)

The method of claim 15, wherein the human liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, are modified to express a mutant STING.

### Claim 22 (depends on 21)

The method of claim 21, wherein the human liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, are transfected or transformed with a mutant STING prior to the treating step.

### Claim 23 (depends on 21)

The method of claim 21, wherein the mutant STING is STING S162A.

### Claim 24 (depends on 15)

The method of claim 15, wherein the liver resident dendritic cells, macrophages, nonparenchymal cells, or any combination thereof, are autologous cells.
